Who are SHR-1316、Chemotherapeutic's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adcetris, Halaven, Jevtana Kit, Taxol, Taxol, Polatuzumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/shr-1316-chemotherapeutic.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

SHR-1316、Chemotherapeutic — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SHR-1316、Chemotherapeutic (SHR-1316、Chemotherapeutic) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microtubule inhibitor. Area: Oncology.

phase 3 Microtubule inhibitor Tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

SHR-1316、Chemotherapeutic (SHR-1316、Chemotherapeutic) — Jiangsu HengRui Medicine Co., Ltd.. SHR-1316 is a chemotherapeutic agent that inhibits tubulin polymerization to disrupt microtubule dynamics and induce cancer cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SHR-1316、Chemotherapeutic TARGET	SHR-1316、Chemotherapeutic	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Microtubule inhibitor	Tubulin
Adcetris	brentuximab-vedotin	Pfizer	marketed	CD30-directed Immunoconjugate [EPC]	Tubulin beta	2011-01-01
Halaven	ERIBULIN	Eisai	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Jevtana Kit	cabazitaxel	Accord Hlthcare	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Taxol	paclitaxel	Pfizer	marketed	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01
Taxol	nab-paclitaxel	Pfizer	marketed	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Polatuzumab	Polatuzumab	National Cancer Institute (NCI)	marketed		B-cell antigen receptor complex-associated protein beta chain, Tubulin beta

Recent regulatory actions (last 90 days)

2026-03-18 — Polatuzumab · FDA · approved · US · National Cancer Institute (NCI)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-10 — Jevtana Kit · 7241907*PED · Compound · US
2026-08-13 — Taxol · 8034375 · Method of Use · US
2026-08-13 — Taxol · 8034375 · US
2026-08-21 — Taxol · 9101543*PED · US
2026-08-21 — Taxol · 8268348*PED · Compound · US
2026-08-21 — Taxol · 7758891*PED · Compound · US
2026-08-21 — Taxol · 9101543*PED · Compound · US
2026-08-21 — Taxol · 8268348*PED · US
2026-08-21 — Taxol · 7758891*PED · US
2027-02-13 — Taxol · 8034375*PED · Compound · US
2027-02-13 — Taxol · 8034375*PED · US
2030-10-27 — Jevtana Kit · 12453712 · Method of Use · US
2030-10-27 — Jevtana Kit · 10583110 · Method of Use · US
2030-10-27 — Jevtana Kit · 10716777 · Method of Use · US
2030-10-27 — Jevtana Kit · 8927592 · Method of Use · US
2031-04-27 — Jevtana Kit · 12453712*PED · Compound · US
2031-04-27 — Jevtana Kit · 8927592*PED · Compound · US
2031-04-27 — Jevtana Kit · 10583110*PED · Compound · US
2031-04-27 — Jevtana Kit · 10716777*PED · Compound · US
2032-03-04 — Taxol · 9393318 · Method of Use · US
2032-03-04 — Taxol · 9597409 · US
2032-03-04 — Taxol · 9393318 · US
2032-03-04 — Taxol · 9597409 · Method of Use · US
2032-09-04 — Taxol · 9393318*PED · Compound · US
2032-09-04 — Taxol · 9597409*PED · Compound · US
2032-09-04 — Taxol · 9393318*PED · US
2032-09-04 — Taxol · 9597409*PED · US
2034-01-12 — Taxol · 9511046 · US
2034-01-12 — Taxol · 9511046 · Method of Use · US
2034-07-12 — Taxol · 9511046*PED · US

Sponsor landscape (Microtubule inhibitor class)

Ma Fei，MD · 2 drugs in this class
Eisai Co., Ltd. · 1 drug in this class
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Nippon Kayaku Co., Ltd. · 1 drug in this class
Shanghai Hengrui Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SHR-1316、Chemotherapeutic — Competitive Intelligence Brief. https://druglandscape.com/ci/shr-1316-chemotherapeutic. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab